Atritech lands $22m in financing:
This article was originally published in Clinica
Developer of the Watchman left atrial appendage system Atritech has closed a $22m round of financing. This round, which was led by SightLine Partners, brings Atritech's total funding over the last 18 months to $45m. The Plymouth, Minnesota-based firm said it will use the proceeds to complete clinical trials of its lead product, which is designed to prevent patients with atrial fibrillation from suffering a stroke by keeping blood clots from forming in the heart.